A Multiple Dose Safety Study of PEG-IFN in Healthy Volunteers
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The primary objectives are to identify the highest safe and well-tolerated dose and frequency
of BIIB017 (PEGylated Interferon Beta-1a) subcutaneous (SC), within the range of 63 to 188
mcg, when given every other week or every 4 weeks to healthy volunteers (HV).